6-溴-3-甲基-1,2,4-噻唑并[4,3-a]-吡啶 | 108281-78-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 中文名称: 6-溴-3-甲基-1,2,4-噻唑并[4,3-a]-吡啶
• 中文别名: 6-溴-3-甲基-[1,2,4]三唑并[4,3-A]吡啶盐酸盐；6-溴-3-甲基-[1,2,4]三唑并[4,3-A]砒啶
• 英文名称: 6-bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine
• CAS: 108281-78-3
• 化学式: C₇H₆BrN₃
• mdl: MFCD08276188
• 分子量: 212.049
• InChiKey: SQJJGTRYJKBHNJ-UHFFFAOYSA-N

物化性质

• 密度：
  1.76±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温、干燥且密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-3-methyl-[1,2,4]triazolo[4,3-a]pyridine
CAS number: 108281-78-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H6BrN3
Molecular weight: 212.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-溴-3-甲基-1,2,4-噻唑并[4,3-a]-吡啶 在 吡啶 、 四(三苯基膦)钯 、 palladium 10% on activated carbon 、 氢气 、 sodium carbonate 、 caesium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 20.0~100.0 ℃ 、101.33 kPa 条件下， 反应 50.0h， 生成 N-(4-(2,4-difluorophenoxy)-3-(3-methyl-[1,2,4]triazolo[4,3-a]pyridine-6-yl)phenyl)-4-methoxybenzenesulfonamide
  参考文献：
  名称：

  新型三唑并吡啶 BRD4 抑制剂作为有效的 HIV-1 潜伏期逆转剂

  摘要：

  含溴结构域蛋白 4 (BRD4) 抑制剂已被证明是抗 HIV-1 潜伏期治疗的一个有前景的选择。我们在此描述了作为 BRD4 抑制剂的三唑并吡啶衍生物的设计、合成和抗 HIV-1 潜伏期生物评价。其中，化合物13d表现出良好的HIV-1再激活能力和显着的安全性，且不会引发异常的免疫激活。当与 PKC 激活剂 Prostratin 联合使用时，它发挥了强大的协同作用，并且通过刺激 Tat 依赖性 HIV-1 延伸，具有与 JQ1 观察到的相同的 BRD4 靶向潜伏机制。此外，它既不影响抗病毒药物的抗病毒功效，也不引起未感染细胞的继发感染，并且13d的潜伏期逆转效力也不受不同类别抗病毒药物的影响。

  DOI：

  10.1021/acsmedchemlett.3c00373
• 作为产物：
  描述：

  2,5-二溴吡啶 在 一水合肼 作用下， 以 吡啶 为溶剂， 反应 38.0h， 生成 6-溴-3-甲基-1,2,4-噻唑并[4,3-a]-吡啶
  参考文献：
  名称：

  （吡啶基）-1,2,4-三唑并[4,3- a ]吡啶的合成

  摘要：

  开发了合成（吡啶基）-1，2，4-三唑并[4，3- a ]吡啶的方法。到所需的中间体2-氯吡啶的主要途径是基于单重排Ñ -oxides 2,2'-联吡啶，2,3'-联吡啶，3,3'-联吡啶，2,4'-联吡啶和4， 4'-联吡啶与三氯氧化磷。3，3′-联吡啶1-氧化物或2，2′-联吡啶1-氧化物与三氯氧化磷反应，得到氯代异构体的混合物。与乙酸酐，3,3'-联吡啶1-氧化物和2,2'-联吡啶1-氧化物反应，仅得到[3,3'-联吡啶] -2（1 H）-one和[2,2'-联吡啶] -6（1 H）-一。

  DOI：

  10.1002/jhet.5570230422

文献信息

• [EN] METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION<br/>[FR] MÉTHODES ET COMPOSÉS DESTINÉS À LA RESTAURATION D'UNE FONCTION DE MUTANTS DE P53
  申请人：PMV PHARMACEUTICALS INC

  公开号：WO2021262684A1

  公开（公告）日：2021-12-30

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促成了癌症的发展和进展。本公开披露描述了一种恢复p53突变体DNA结合亲和力的化合物和方法。本公开披露的化合物可以结合突变型p53，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应子的能力。披露的化合物可用于减少含有p53突变的癌症的进展。
• [EN] [1,2,4]TRIAZOLO[4,3-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS<br/>[FR] COMPOSÉS D'INDOLE SUBSTITUÉS PAR [1,2,4]TRIAZOLO[4,3-A] PYRIDINYLE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019028301A1

  公开（公告）日：2019-02-07

  Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R2, R3, R4a, R4b, R4c, R4d, R5, n, and p are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

  揭示了化合物的结构式（I）或其盐，其中R1、R2、R3、R4a、R4b、R4c、R4d、R5、n和p在此处被定义。还揭示了使用这些化合物作为信号通过Toll样受体7、8或9的抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗炎症性和自身免疫性疾病方面是有用的。
• 三氮唑类化合物及其制备方法和应用
  申请人：山东大学

  公开号：CN110272418B

  公开（公告）日：2020-10-16

  本发明提供一种三氮唑类化合物及其制备方法和应用，本发明提供的三氮唑化合物或其药学上可接受的盐，其具有式(I)所示结构：其中，R1、R2、R3各自独立地选自‑SO2R4、‑SO2R5、COR6、H和卤素；R4、R5、R6各自独立地选自芳基、杂芳基、直链或支链的烷基、烯基和环烷基；其中，所述芳基、杂芳基、直链或支链的烷基、烯基和环烷基是未被取代的或被R7取代的；R7选自卤素、C1‑5直链或支链的烷基、卤代烷基、C1‑5直链或支链的烷氧基和硝基。该类化合物对BRD4具有较好抑制活性、具有HIV潜伏病毒感染激活活性，并且毒性低，具有较好的成药性和更潜在的临床应用价值。
• Fused Heterocyclic Compounds as Ion Channel Modulators
  申请人：Kobayashi Tetsuya

  公开号：US20120010192A1

  公开（公告）日：2012-01-12

  The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.

  本公开涉及一类是钠通道抑制剂的化合物，以及它们在治疗各种疾病状态中的应用，包括心血管疾病和糖尿病。在特定实施例中，该类化合物的结构由式I给出：其中R1、R2、R3、R4和R5如本文所述，以及制备和使用该类化合物的方法，以及含有这些化合物的药物组合物。
• 2,5-Methano- and 2,5-Ethano-Tetrahydrobenzazepine Derivatives And Use Thereof To Block Reuptake Of Norepinephrine, Dopamine, and Serotonin
  申请人：GUZZO Peter R.

  公开号：US20120046271A1

  公开（公告）日：2012-02-23

  The compounds of the present invention are represented by the following 2,5-methano- and 2,5-ethano-tetrahydrobenzazepine derivatives having formula (I): where the carbon atom designated * is in the R or S configuration when n is 1 and the substituents X and R 1 -R 7 are as defined herein.

  本发明的化合物由以下具有式（I）的2,5-甲基和2,5-乙基-四氢苯并哌啶衍生物表示：其中当n为1时，指定为*的碳原子为R或S构型，取代基X和R1-R7如下所定义。